1188
J. Atzrodt et al.
5-(4-tert.-Butyl-phenylamino)-2-phenyl-imidazol-4-one (10b; C19H19N3O)
Yield: 0.14 g (47%); yellow crystals; m.p.: 215ꢀC; 1H NMR (250 MHz, ꢁ, DMSO-d6): 8.19 (d,
J 8:65 Hz, 2H), 7.61 (m, 3H), 7.43 (d, J 8:44 Hz, 2H), 7.37 (d, J 8:58 Hz, 2H), 1.31 (s, 9H)
ppm; 13C NMR (62 MHz, ꢁ, DMSO-d6): 145.0, 138.8, 133.9, 128.9, 128.4, 128.2, 128.0, 127.6,
125.7, 125.4, 124.9, 34.3, 31.1 ppm; MS (CI): m/z (%) 307 [MH ] (96), 292 (100), 276 (27), 159
(96), 149 (36), 134 (95), 117 (32), 104 (66), 91 (17), 77 (50); UV/Vis (DMSO): ꢃmax (lg") 286
(4.10), 379 (3.64), 426 (3.65) nm.
2-(4-Ethylsulfanyl-2-phenyl-5-phenylamino-4H-imidazol-4-yl)-but-2-en-dicarboxylicacid
dimethylester (11a; C24H25N3O4S)
A solution of 0.6 g 6a (1.0 mmol) and 0.3 g acetylenedimethyldicarboxylate (2.0 mmol) dissolved in
20 cm3 THF was heated for 3 h under re¯ux. The formation of a colourless product could be
monitored by TLC. After completion of the reaction, the solvent was evaporated, and the residue was
puri®ed by column chromatography (ethylacetate/n-heptane 1:5).
1
Yield: 0.2 g (45%); colourless solid; m.p.: 101ꢀC; H NMR (400 MHz, ꢁ, CDCl3): 9.47 (s, 1H,
NH), 8.38 (d, J 8:04 Hz, 2H, o-Ph), 7.76 (d, J 8:44 Hz, 2H, Tol), 7.54±7.45 (m, 3H, m-, p-Ph),
7.20 (d, J 8:25 Hz, 2H, Tol), 3.96 (s, 3H, CH3OOC), 3.70 (s, 3H, CH3OOC), 2.60 (m, 2H, CH2),
2.34 (s, 3H, CH3-Tol), 1.19 (t, J 7:48 Hz, 3H, CH3) ppm; 13C NMR (100 MHz, ꢁ, CDCl3): 178.2,
175.5, 169.4, 164.7, 143.1, 136.1, 133.8, 131.8, 131.6, 129.5, 129.2, 128.3, 124.1, 119.5, 83.9, 53.3,
52.1, 24.5, 20.8, 14.0 ppm; MS (CI): m/z (%) 452 [MH ] (100), 420 (5), 390 (63), 358 (4), 269
(10), 143 (7).
General procedure for the synthesis of imidazo[4,5-b]azepines 12
A solution of 0.5 mmol 6 and 0.3 g acetylenedimethyldicarboxylate (2.0 mmol) in 20 cm3 toluene
was heated under re¯ux for two days. The colourless product 11 was ®rst formed which then slowly
added a second molecule acetylenedimethyldicarboxylate to give the ®nal product 12 which was
purple. After completion of the reaction the solvent was evaporated and the residue was puri®ed by
column chromatography (ethylacetate/n-heptane 1:5) to yield the imidazo[4,5-b]azepines 12.
2-Phenyl-9-(4-tolyl)-1H-imidazo[4,5-b]azepin-5,6,7,8-tetracarboxylic
acid tetramethylester (12a; C28H25N3O8)
1
Yield: 0.08 g (31%) purple crystals; m.p.: 166±167ꢀC; H NMR (250 MHz, ꢁ, CDCl3): 7.54 (d,
J 7:84 Hz, 2H), 7.46±7.35 (m, 3H), 7.25 (d, J 8:71 Hz, 2H), 7.05 (d, J 8:30 Hz, 2H), 6.66 (s,
1H, NH), 3.90 (s, 3H), 3.86 (s, 3H), 3.81 (s, 3H), 3.13 (s, 3H), 2.26 (s, 3H) ppm; 13C NMR (62 MHz,
ꢁ, CDCl3): 166.6, 165.6, 163.8, 160.9, 141.0, 140.5, 139.4, 131.4, 130,8, 130.5, 129.9, 129.8, 129.6,
128.9, 128.7, 127.3, 125.7, 125.1, 116.7, 53.6, 53.1, 52.9, 52.3, 20.6 ppm; MS (EI): m/z (%) 531
[M ] (100), 498 (10), 413 (17), 381 (44), 357 (15), 310 (17), 252 (22), 194 (17), 91 (37); UV/Vis
(CHCl3): ꢃmax (lg") 259 (4.24), 350 (3.81), 521 (3.33) nm.
2-Phenyl-9-(4-tert.-butyl-phenyl)-1H-imidazo[4,5-b]azepin-5,6,7,8-tetracarboxylicacid
tetramethylester (12b; C31H31N3O8)
Yield: 0.06 g (12%); purple solid; m.p.: 158±162ꢀC; 1H NMR (400 MHz, ꢁ, CDCl3): 7.55 (d,
J 7:96 Hz, 2H), 7.43 (m, 3H), 7.32 (m, 4H), 3.90 (s, 3H), 3.86 (s, 3H), 3.81 (s, 3H), 3.13 (s, 3H),
1.27 (s, 9H) ppm; 13C NMR (100 MHz, ꢁ, CDCl3): 143.9, 129.7, 128.9, 128.7, 127.2, 126.2, 125.8,
116.3, 53.5, 53.1, 52.8, 52.2, 31.4 ppm; MS (CI): m/z (%) 574 [MH ] (100).